Phaseline

Companies › Mineralys Therapeutics

Mineralys Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Cardiovascular; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
lorundrostat
Aldosterone synthase inhibitor
CYP11B2Phase 3HypertensionMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05968430lorundrostatPhase 3HypertensionCardiovascularMay 2027

From the company's SEC filings

Cash of $101m on 2026-09-30; operating cash outflow about $154m a year; runway about 8 months at that burn, to May 2027; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 10 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

CYP11B2 (1)

Companies with the same targets

AstraZeneca

Companies built like this

Gossamer Bio USA Grace Therapeutics Trust Bio-sonics Liquidia Technologies EVD Pharmacy and Medical Company

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.